Ipx-380 Direct

IPX-380 exerts its therapeutic effects by selectively binding to the S1P1 receptor, leading to its activation. This activation results in the internalization of the receptor, which in turn reduces the number of lymphocytes in the circulation and tissues. By decreasing lymphocyte counts, IPX-380 can mitigate inflammation and tissue damage associated with autoimmune and inflammatory diseases.

The S1P1 receptor is a G protein-coupled receptor that plays a crucial role in regulating various cellular processes, including cell migration, differentiation, and survival. It is highly expressed on the surface of immune cells, such as lymphocytes, and is involved in the modulation of immune responses. The S1P1 receptor is also implicated in the pathogenesis of several autoimmune and inflammatory diseases, including multiple sclerosis, rheumatoid arthritis, and psoriasis. ipx-380

IPX-380, also known as crisaborole, is a small molecule drug that has gained significant attention in recent years due to its therapeutic potential in treating various inflammatory and autoimmune disorders. Specifically, IPX-380 is a potent and selective agonist of the S1P1 receptor, a subtype of the sphingosine-1-phosphate (S1P) receptor family. The S1P1 receptor is a G protein-coupled receptor